Impact of High-Risk Cytogenetics on Outcomes for Children and Young Adults Receiving CD19-Directed CAR T-cell Therapy
CAR T-cell treatment can result in long-term remissions of relapsed/refractory B-acute...
Read More
Search Physician’s Weekly
Search for articles, editorials, meeting coverage, podcasts, and more
Showing 21 - 40 of 443 results for 'CAR T-cell'
Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B cell lymphoma.
Anti CD19 Chimeric Antigen Receptor (CAR) T-cell therapy has transformed the care of relapsed & refractory aggressive B cell Lymphoma. However, financial toxicity and manufacturing time represent barriers to its widespread...
Read More
FDA Approves CAR T-Cell Tx for Relapsed/Refractory B-Cell ALL
ZUMA-3 shows single-dose IV infusion achieved complete response in more than half of patients The...
Read More
How Does CAR T-Cell Therapy Work in Treating Patients
Adoptive cell therapy using chimeric antigen receptor (CAR) T cells augments the ability of the...
Read More
CAR T-Cell Tx Shows Efficacy for Relapsed/Refractory B-Cell Lymphoma
Study suggests results could change treatment paradigm for this patient population A single...
Read More
Balancing the CAR T: perspectives on efficacy and safety of CAR T-cell therapy in hematologic malignancies.
Chimeric antigen receptor (CAR) T-cell therapy is an example of how immunotherapy is...
Read More
The Current and Future Role of Radiation Therapy in the Era of CAR T-cell Salvage.
Radiation therapy has the potential to modulate the immune system in a variety of ways, and given...
Read MoreCAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma.
Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell related adverse event and remains poorly understood. In this multicenter analysis, we studied patterns of hematopoietic reconstitution and evaluated...
Read More
ASH: CAR T-Cell Therapy Promising for Relapsed/Refractory iNHL
WEDNESDAY, Dec. 9, 2020 (HealthDay News) — Axicabtagene ciloleucel (axi-cel), an autologous...
Read MoreAdvertisement
![[Perspectives on CAR T-cell treatment].](https://cdn.physiciansweekly.com/wp-content/uploads/2022/12/Leukemia-lymphoma-blood-cancer-e1735681348512.jpg)
[Perspectives on CAR T-cell treatment].
CARTs (T-cells with a chimeric antigen receptor) are one of the most innovative and exciting...
Read More
CAR T-Cell Therapy an Unmitigated Success in Relapsed/Refractory DLBCL
Management of the cytokine release syndrome seen in association with CAR T-cell therapy best done...
Read More
Monitoring CAR T-cells using flow cytometry.
Chimeric antigen receptor (CAR) T-cell therapy is considered as a major scientific breakthrough in...
Read More
Infection Risk Up in Month After CAR T-Cell Immunotherapy
FRIDAY, May 29, 2020 (HealthDay News) — For children and young adults receiving CD19...
Read MoreA Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies.
Chimeric antigen receptor (CAR) T cells are genetically engineered T lymphocytes that express a synthetic receptor that recognizes a tumor cell surface antigen, which causes the T lymphocyte to kill the tumor cell. As of...
Read More
CARv3-TEAM-E T-Cell Treatment Beneficial for Recurrent Glioblastoma
THURSDAY, March 21, 2024 (HealthDay News) — For patients with recurrent glioblastoma,...
Read MoreTackling Esophageal Squamous Cell Carcinoma with ITFn-Pt(IV): A Novel Fusion of PD-L1 Blockade, Chemotherapy, And T-cell Activation.
PD-1/PD-L1 blockade immunotherapy has gained approval for the treatment of a diverse range of tumors; however, its efficacy is constrained by the insufficient infiltration of T lymphocytes into the tumor microenvironment,...
Read More
Clinicopathologic characterization of cutaneous adult T-cell leukemia/lymphoma: A single tertiary care center experience in the United States.
Adult T-cell leukemia/lymphoma (ATLL) is a rare aggressive T-cell leukemia/lymphoma associated...
Read More
For Large B-Cell Lymphoma, Chimeric Antigen Receptor T-Cell Therapy Is Superior to Standard of Care
For recurrent or refractory large B-cell lymphoma (LBCL), high-dose chemotherapy followed by...
Read More
A clinically applicable prediction model to improve T-cell collection in CAR-T cell therapy.
As chimeric antigen receptor T (CAR-T) cell therapy targeting CD19 has shown favorable outcomes in...
Read MoreTargeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma.
Pivotal clinical trials of B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma (MM) resulted in remarkable initial responses, which led...
Read More